Fact CheckerSign in

NCT07532447Completed

Metabolomic Characteristics of Patients With Non-small Cell Lung Cancer in Plasma, Tissue and Exhaled Breath Condensate

Metabolomic Characteristics of Patients With Non-small Cell Lung Cancer in Plasma, Tissue and Exhaled Breath Condensate: A Case-control Study

Source: ClinicalTrials.gov · Last updated 20 Apr 2026

Brief summary (registry, in English)

Investigators collected tissue and plasma samples from patients with benign pulmonary nodules and non-small cell lung cancer (NSCLC). Exhaled breath condensate (EBC) samples were obtained from these patients using a breath condenser. Differential metabolites were identified in samples from 22 NSCLC patients and 20 benign controls using ultra-performance liquid chromatography-high resolution mass spectrometry-based untargeted metabolomics.

Status (registry)
Completed
Study type
Observational
Enrollment
74 (actual)
First submitted
8 Apr 2026
Start date
30 Apr 2022
Primary completion date
31 Dec 2025
Lead sponsor
People's Hospital of Xinjiang Uygur Autonomous Region
NCT number
NCT07532447

What you commit to

  • Study type: Observational
  • Participants enrolled: 74
  • From 30 Apr 2022 to the primary completion date, 31 Dec 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Metastatic lung cancer

Who the study is looking for

  • Patients with non-small cell lung cancer or benign pulmonary nodules

Sex: All

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
People's Hospital of Xinjiang Uygur Autonomous Region
Coordinator of this site? Confirm its status
ÜrümqiChinaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.